Severe cutaneous adverse rxns up in allopurinol initiators

April 23, 2013
Severe cutaneous adverse rxns up in allopurinol initiators
Allopurinol initiators have an almost 10-fold increased risk of severe cutaneous adverse reactions compared with nonusers, according to a study published in the April issue of Arthritis Care & Research.

(HealthDay)—Allopurinol initiators have an almost 10-fold increased risk of severe cutaneous adverse reactions (SCARs) compared with nonusers, according to a study published in the April issue of Arthritis Care & Research.

Seoyoung C. Kim, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a propensity-score matched cohort study using data from five large Medicaid programs to examine the incidence rate and in-hospital mortality of hospitalization for in allopurinol initiators compared with non-allopurinol users.

During 65,625 person-years of follow-up for allopurinol initiators, the researchers found that 45 patients were hospitalized for SCARs, with a crude incidence ratio of 0.69 per 1,000 person-years. All cases occurred within 365 of initiating treatment with allopurinol and 91.1 percent occurred within 180 days. During the hospitalization, 26.7 percent of patients died. For non-allopurinol users, the crude incidence rate was 0.04 per 1,000 person-years. For allopurinol initiators versus nonusers, the risk of SCARs was significantly increased (hazard ratio, 9.68). After adjustment for age, comorbidities, and recent diuretic use, the hazard ratio for high-dosage (>300 mg/day) versus low-dosage allopurinol was 1.30 for allopurinol users.

"Our study suggests that the risk of SCARs was 10 times as high in allopurinol initiators as compared to non-allopurinol users," the authors write. "Future studies using a large detailed clinical data set from a large prospective inception cohort of users is needed for a better understanding of other risk factors of SCARs such as impaired renal function and concomitant medication use."

Several authors disclosed financial ties to pharmaceutical companies, including Takeda, which partially funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Gout drug offers hope for heart disease patients

March 5, 2013

(Medical Xpress)—Research at the University of Dundee has shown than an old, inexpensive anti-gout drug has benefits for heart disease sufferers and has the potential to one day help prevent heart disease, sudden deaths ...

Recommended for you

Team finds gene that confirms existence of psoriatic arthritis

February 5, 2015

PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage. Nearly all patients with PsA also have skin psoriasis and, in many cases, the skin disease ...

Blocking one receptor could halt rheumatoid arthritis

September 10, 2014

Researchers at the University of Illinois at Chicago College of Medicine have shown for the first time how the activation of a receptor provokes the inflammation and bone degradation of rheumatoid arthritis—and that activation ...

Low back pain? Don't blame the weather

July 10, 2014

Australian researchers reveal that sudden, acute episodes of low back pain are not linked to weather conditions such as temperature, humidity, air pressure, wind direction and precipitation. Findings published in Arthritis ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.